 |
 |

Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy
Lucy Q. Shen, MD;
Angie Child, MD;
Griffin M. Weber, MD, PhD;
Judah Folkman, MD ;
Lloyd Paul Aiello, MD, PhD
Arch Ophthalmol. 2008;126(6):793-799.
Objective To evaluate whether rosiglitazone maleate, an oral peroxisome-proliferating activated receptor agonist and oral insulin sensitizing agent with potential antiangiogenic activity, delays onset of proliferative diabetic retinopathy (PDR).
Methods Longitudinal medical record review of all patients treated with rosiglitazone receiving both medical and ophthalmic care at the Joslin Diabetes Center from May 1, 2002, to May 31, 2003 (N = 124), and matched control patients not taking a glitazone drug (N = 158). The mean duration of follow-up was 2.8 years (range, 0.3-9.0 years).
Results Baseline characteristics and final hemoglobin A1c values (7.6% and 7.8%, respectively) were similar in the rosiglitazone and control groups (P = .10). In eyes with severe nonproliferative diabetic retinopathy at baseline (rosiglitazone group, 14 eyes; control group, 24 eyes), progression to PDR over 3 years occurred in 19.2% in the rosiglitazone group and 47.4% in the control group, representing a 59% relative risk reduction (Wilcoxon, P = .045; log-rank, P = .059). Fewer eyes in the rosiglitazone group experienced 3 or more lines of visual acuity loss (P = .03). The incidence of diabetic macular edema was similar in both groups.
Conclusions Rosiglitazone may delay the onset of PDR, possibly because of its antiangiogenic activity. Future clinical investigations should consider analysis of this potential benefit along with ongoing evaluation of potential cardiac risk in studies where the risk-benefit profiles are deemed appropriate.
Author Affiliations: Harvard Medical School (Drs Shen, Child, Weber, Folkman, and Aiello), Beth Israel Deaconess Medical Center (Dr Weber), Children's Hospital Boston (Dr Folkman), and Beetham Eye Institute and Eye Research Section, Joslin Diabetes Center (Dr Aiello), Boston, Massachusetts; and Jules Stein Eye Institute, University of California–Los Angeles (Dr Shen). Died January 14, 2008.
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
RELATED LETTERS
Association of Proliferative Diabetic Retinopathy With Insulin Use and Microalbuminuria
Shu-Hsun Chun and Ai-Hsien Li
Arch Ophthalmol. 2010;128(1):146.
EXTRACT
| FULL TEXT
Association of Proliferative Diabetic Retinopathy With Insulin Use and Microalbuminuria—Reply
Lloyd Paul Aiello and Lucy Q. Shen
Arch Ophthalmol. 2010;128(1):146-147.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
 |
Association of Proliferative Diabetic Retinopathy With Insulin Use and Microalbuminuria
Chun and Li
Arch Ophthalmol 2010;128:146-146.
FULL TEXT
Thiazolidinediones Reduce Pathological Neovascularization in Ischemic Retina Via an Adiponectin-Dependent Mechanism
Higuchi et al.
Arterioscler. Thromb. Vasc. Bio. 2010;30:46-53.
ABSTRACT
| FULL TEXT
Association of Proliferative Diabetic Retinopathy With Insulin Use and Microalbuminuria--Reply
Aiello and Shen
Arch Ophthalmol 2010;128:146-147.
FULL TEXT
Challenges in Understanding Diabetic Embryopathy
Loeken
Diabetes 2008;57:3187-3188.
FULL TEXT
|